

# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



20<sup>th</sup> May 2026

The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejheebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Scrip Code - 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.  
**Scrip Code-**  
**APOLLOHOSP**  
**ISIN INE437A01024**

Dear Sirs,

Re: Intimation of outcome of Board Meeting under Regulations 30, 33, and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations")

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letters dated March 24, 2026, and May 4, 2026, we wish to inform you that the Board of Directors ('Board') of the Company at its meeting held today, i.e., May 20, 2026, inter alia, transacted the following items of business:

## 1. Financial Results

- Audited Standalone financial results of the Company for the three months and year ended 31<sup>st</sup> March 2026 along with the Audit Report on the standalone financial statements.
- Audited Consolidated financial results of the Company for the three months and year ended 31<sup>st</sup> March 2026 along with the Audit Report on the consolidated financial statements.
- Declaration that the statutory auditors have issued audit reports with unmodified opinion on financial statements.
- The above said documents are being posted on the website of the Company i.e., [www.apollohospitals.com](http://www.apollohospitals.com).
- The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.

The said audited financial results for the financial year ended March 31, 2026 and the auditors' reports thereon are attached herewith - Annexure - 1.



IS/ISO 9001 : 2000

**Regd. Office :**  
19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**  
"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)

# APOLLO HOSPITALS ENTERPRISE LIMITED



CIN : L85110TN1979PLC008035

## 2. Dividend

Recommended a final dividend of ₹10/- per Equity Share (200%) of the face value of ₹5/- per share to the shareholders of the Company for the FY2025-26.

The dividend recommended by the Board of Directors of the Company is subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.

## 3. Convening Annual General Meeting

The Annual General Meeting of the Company is scheduled to be held on **Tuesday, 25<sup>th</sup> August 2026 through video conferencing and other audio-visual means.**

## 4. Fixation of Record Date

The Board has fixed the record date as Friday, 14<sup>th</sup> August 2026 for the purpose of determining the names of the shareholders who are entitled for the final dividend and also for the purpose of the Annual General Meeting.

## 5. Dividend payment date

The dividend, if declared at the Annual General Meeting will be paid on or before 10<sup>th</sup> September 2026.

## 6. Re-appointment of Executive Director

Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of Dr. Prathap C Reddy, as Executive Chairman for a further period of two years with effect from 25<sup>th</sup> June 2026, subject to approval of members at the ensuing Annual General Meeting.

Dr. Prathap C Reddy is not debarred from holding the office as a Director by virtue of any SEBI Order or any other authority.

The details as required under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 2.

## 7. Re-appointment of Independent Director

Ms. Rama Bijapurkar (DIN 00001835) is an Independent Director of the Company, whose first five-year term as an Independent Director expires on 12<sup>th</sup> November 2021.

Pursuant to the provisions of Section 149 of the Companies Act, 2013 and Regulation 16 & 25 of the SEBI Listing Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the proposal of re-appointment of Ms. Rama Bijapurkar as an Independent Director for a second term of five consecutive years from 12<sup>th</sup> November 2026 to 11<sup>th</sup> November 2031, subject to approval of the Shareholders of the Company by way of special resolution at the ensuing Annual General Meeting.

IS/ISO 9001 : 2000

### Regd. Office :

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

### General Office :

"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : investor.relations@apollohospitals.com

Website : www.apollohospitals.com



# APOLLO HOSPITALS ENTERPRISE LIMITED



CIN : L85110TN1979PLC008035

Ms. Rama Bijapurkar is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, are not disqualified to be re-appointed as Independent Director.

The details as required under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 3.

## 8. Transaction Proposal

The Board approved a transaction involving Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company, and Kids Clinic India Limited ("Cloudnine").

Pursuant to the transaction, AHLL will divest its stake in Apollo Specialty Hospitals Private Limited (ASHPL) and Apollo Fertility Centre Private Limited (AFCPL) to Kids Clinic India Limited at an enterprise value of approximately Rs.15,500 million, for a combination of cash consideration of Rs. 7,650 million and an equity stake of approximately 9.9% in Kids Clinic India Limited at a consideration of Rs. 7,850 million.

Consequent to the transaction, ASHPL and AFCPL will cease to be subsidiaries of the Company.

The transaction is subject to customary closing conditions and receipt of necessary regulatory approvals, including approval of the Competition Commission of India ("CCI").

The details as required under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 4.

## 9. Merger of Apollo Hospitals North Ltd into the Company

The Board of Directors approved the proposal of Merger of M/s. Apollo Hospitals North Limited (Wholly Owned Subsidiary) into Apollo Hospitals Enterprise Limited ('Holding Company' or the 'Company') subject to the receipt of necessary statutory approvals in accordance with the provisions of the Companies Act, 2013 through the National Company Law Tribunal route.

The details required under the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Master Circular dated November 11, 2024, including amendments thereto are as follows:

The details as required under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 5.

## 10. Disclosure Requirements for Large Corporates

Pursuant to SEBI Circular No. SEBI/HO/DDHS/DDHSRACPODI/P/CIR/2023/ 172 dated October 19, 2023, and emails received from BSE Limited and National Stock Exchange of India Limited, we hereby furnish the following details for the financial year ended 31<sup>st</sup> March 2026.

IS/ISO 9001 : 2000

**Regd. Office :**  
19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**  
"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : investor\_relations@apollohospitals.com  
Website : www.apollohospitals.com



# APOLLO HOSPITALS ENTERPRISE LIMITED



CIN : L85110TN1979PLC008035

Sl.No.	Particulars	Amount (Rs. in crores)
1	Outstanding Qualified Borrowings at the start of the financial year	Rs.1,783.23
2	Outstanding Qualified Borrowings at the end of the financial year	Rs.1,822.22
3	Credit rating (highest in case of multiple ratings)	Credit Rating : AAA Credit Rating Agency : ICRA Ltd Credit Rating : AA+ Credit Rating Agency : Crisil Ltd
4	Incremental borrowing done during the year	Rs.671.00
5	Borrowings by way of issuance of debt securities during the year	Nil

The Board meeting commenced at 1.15 p.m (IST) and concluded at ..... p.m. (IST).

5.30

Kindly take on record the same.

Thanking You

Yours faithfully  
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN  
Sr. VICE PRESIDENT - FINANCE  
AND COMPANY SECRETARY



## Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
 Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
 Website: www.apollohospitals.com

## Statement of Standalone Financial Results for the three months and the year ended March 31, 2026

(Rs. in Million)

Particulars	Three months ended 31/03/2026	Preceding three months ended 30/12/2025	Corresponding three months ended 31/03/2025	Current year ended 31/03/2026	Previous year ended 31/03/2025
	Refer note 2	Unaudited	Refer note 2	Audited	Audited
<b>1 Income</b>					
(a) Revenue from operations	24,385	23,637	20,753	93,262	82,021
(b) Other income	903	1,080	916	3,718	3,477
<b>Total income (a + b)</b>	<b>25,288</b>	<b>24,717</b>	<b>21,669</b>	<b>96,980</b>	<b>85,498</b>
<b>2 Expenses</b>					
(a) Cost of materials consumed	6,062	6,117	5,620	24,188	22,484
(b) Employee benefits expense	4,412	4,101	4,102	16,862	15,968
(c) Finance costs	634	617	631	2,417	2,540
(d) Depreciation and amortisation expenses	1,280	1,268	1,298	5,004	4,494
(e) Other expenses	7,956	7,484	5,818	28,932	23,127
<b>Total expenses</b>	<b>20,344</b>	<b>19,587</b>	<b>17,469</b>	<b>77,403</b>	<b>68,613</b>
<b>3 Profit before tax and exceptional items (1) - (2)</b>	<b>4,944</b>	<b>5,130</b>	<b>4,200</b>	<b>19,577</b>	<b>16,885</b>
4 Exceptional item (Refer note 8)	-	(114)	-	(114)	-
<b>5 Profit before tax (3) + (4)</b>	<b>4,944</b>	<b>5,016</b>	<b>4,200</b>	<b>19,463</b>	<b>16,885</b>
<b>6 Tax expense</b>					
Current tax	1,382	1,066	992	4,573	4,055
Deferred tax	(262)	115	(126)	(36)	(133)
<b>7 Profit after tax for the period / year (5) - (6)</b>	<b>3,824</b>	<b>3,835</b>	<b>3,334</b>	<b>14,926</b>	<b>12,963</b>
<b>8 Other comprehensive income/(loss)</b>					
Items that will not be reclassified to profit or loss					
(a) Remeasurement gains/(losses) on defined benefit plans	(78)	(32)	2	(142)	3
(b) Net change in fair value of investments in equity instruments measured at fair value	(10)	-	-	(10)	-
(c) Income tax relating to items that will not be reclassified to profit or loss	20	8	(0)	36	(1)
<b>Total other comprehensive income/ (loss)</b>	<b>(68)</b>	<b>(24)</b>	<b>1</b>	<b>(116)</b>	<b>2</b>
<b>9 Total comprehensive income for the period/year (7) + (8)</b>	<b>3,756</b>	<b>3,811</b>	<b>3,335</b>	<b>14,810</b>	<b>12,965</b>
10 Paid-up equity share capital (Face value Rs.5/- per share)				719	719
11 Reserves (excluding revaluation reserves)				98,913	86,623
<b>12 Earnings per equity share ('EPS') of Rs.5/- each</b>					
Basic EPS for the period/year (Rs.)	*26.59	*26.67	*23.18	103.81	90.15
Diluted EPS for the period/year (Rs.)	*26.56	*26.67	*23.18	103.74	90.15
<b>13 Additional Information :-</b>					
<b>Earnings before finance costs, tax, depreciation and amortization, other income, exceptional items (EBITDA) (refer foot note)</b>	<b>5,955</b>	<b>5,935</b>	<b>5,213</b>	<b>23,280</b>	<b>20,442</b>

\*Not annualised

## Foot note:

1 The Company has presented EBITDA additionally as part of standalone financial results.

For APOLLO HOSPITALS/ENTERPRISE LTD

  
 SUNEETA REDDY  
 Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

## Standalone Balance Sheet

(Rs. in Million)

Particulars	As at 31-Mar-26 Audited	As at 31-Mar-25 Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	54,452	49,105
(b) Right-of-use assets	13,767	13,285
(c) Capital work-in-progress	3,015	2,940
(d) Other intangible assets	945	1,091
(e) Intangible assets under development	182	125
(f) Financial assets		
(i) Investments	38,769	24,790
(ii) Loans	5,589	4,291
(iii) Other financial assets	1,730	1,530
(g) Income tax asset (net)	376	290
(h) Other non-current assets	1,816	1,092
<b>Total non-current assets</b>	<b>120,640</b>	<b>98,539</b>
<b>Current assets</b>		
(a) Inventories	1,468	1,266
(b) Financial assets		
(i) Investments	10,158	14,317
(ii) Trade receivables	8,473	8,148
(iii) Cash and cash equivalents	3,426	2,332
(iv) Bank balances other than (iii) above	61	3,609
(v) Loans	753	221
(vi) Other financial assets	1,372	1,723
(c) Contract assets	1,013	1,080
(d) Other current assets	1,780	2,488
<b>Total current assets</b>	<b>28,504</b>	<b>35,184</b>
<b>Total assets</b>	<b>149,144</b>	<b>133,723</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	719	719
(b) Other equity	98,913	86,623
<b>Total equity</b>	<b>99,632</b>	<b>87,342</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	16,250.3	15,535.3
(ii) Lease liabilities	13,257	12,782
(iii) Other financial liabilities	18	12
(b) Deferred tax liabilities (net)	3,560	3,632
(c) Other non-current liabilities	12	13
<b>Total non-current liabilities</b>	<b>33,097</b>	<b>31,974</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	1,971.9	2,296.9
(ii) Lease liabilities	416	282
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	968	627
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	8,589	7,600
(iv) Other financial liabilities	1,598	1,002
(b) Other current liabilities	1,785	1,323
(c) Provisions	1,087	1,276
<b>Total current liabilities</b>	<b>16,415</b>	<b>14,407</b>
<b>Total liabilities</b>	<b>49,512</b>	<b>46,381</b>
<b>Total equity and liabilities</b>	<b>149,144</b>	<b>133,723</b>

FOR APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

## Statement of Standalone Cash Flows

(Rs. in Million)

PARTICULARS	For the year ended March 31, 2026	For the year ended March 31, 2025
<b>A. Cash flow from Operating Activities</b>		
<b>Profit for the year</b>	<b>14,926</b>	<b>12,963</b>
<b>Adjustments for:</b>		
Depreciation and amortisation expenses	5,004	4,494
Income Tax expense	4,573	4,055
(Profit)/loss on sale of property plant & equipment	40	6
Profit on sale of investments (net)	(228)	(132)
Impairment in value of investment	-	20
Gain on fair valuation of mutual funds	(618)	(633)
Gain on fair valuation of equity investments	(6)	(7)
Finance costs	2,417	2,540
Interest from banks/others	(818)	(845)
Dividend on non-current equity investments	(1,958)	(1,766)
Expected credit loss on trade receivables	437	273
Unrealised foreign exchange (gain)/loss (net)	11	4
Provision written back	(5)	-
Share based payment expense	324	-
<b>Operating Profit before working capital changes</b>	<b>24,099</b>	<b>20,972</b>
<b>Adjustments for (increase)/decrease in operating assets</b>		
Inventories	(202)	(79)
Trade receivables	(762)	(337)
Other financial assets	(506)	265
Other assets	629	(571)
	<b>(841)</b>	<b>(722)</b>
<b>Adjustments for increase/(decrease) in operating liabilities</b>		
Trade payables	1,322	647
Other financial liabilities	571	(216)
Provisions	(326)	266
Other liabilities	461	222
	<b>2,028</b>	<b>919</b>
<b>Cash generated from operations</b>	<b>25,286</b>	<b>21,169</b>
Net income tax paid	(4,695)	(3,750)
<b>Net cash generated from operating activities (A)</b>	<b>20,591</b>	<b>17,419</b>
<b>B. Cash flow from investing Activities</b>		
Purchase of Property, plant and equipment, capital work-in-progress and intangibles	(10,529)	(8,582)
Proceeds from sale of property, plant and equipment	127	137
Consideration received from Apollo HealthCo Limited on reorganisation of pharmacy distribution business	-	12,008
Loans given	(5,066)	(3,130)
Repayments received towards loans	3,237	1,855
Purchase of non-current investments	(13,986)	(5,426)
Purchase of current investments	(16,818)	(24,868)
Proceeds from sale of current investments	22,052	18,151
Proceeds from sale of non-current investments	3	-
Proceeds from/(Investment in) bank deposits	3,548	(2,948)
Interest received	1,344	580
Dividend received from subsidiaries and associates	1,958	1,766
<b>Net cash used in investing activities (B)</b>	<b>(14,130)</b>	<b>(10,457)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from borrowings	6,710	-
Payments towards lease liability	(1,279)	(1,102)
Repayment of borrowings	(6,320)	(1,726)
Finance costs	(1,602)	(1,831)
Dividends paid	(2,876)	(2,732)
<b>Net cash used in financing activities (C)</b>	<b>(5,367)</b>	<b>(7,391)</b>
Net Increase/(decrease) in cash and cash equivalents (A+B+C) = (D)	1,094	(429)
<b>Cash and cash equivalents at the beginning of the year (E)</b>	<b>2,332</b>	<b>2,761</b>
<b>Cash and cash equivalents at the end of the year (D) +(E)</b>	<b>3,426</b>	<b>2,332</b>
<b>Cash and cash equivalents comprises of</b>		
- Cash on hand	80	76
- Balance with banks	3,346	2,256
<b>Total cash and cash equivalents at the end of the period</b>	<b>3,426</b>	<b>2,332</b>

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

## NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS:

1. The standalone financial results ("the Statement") of **Apollo Hospitals Enterprise Limited** ("the Company") for the three months and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 19, 2026 and May 20, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the standalone financial results for the three months ended March 31, 2026 and have expressed an unmodified audit opinion on the financial results for the year ended March 31, 2026.
2. The standalone financial results for the three months ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited standalone figures for the respective years ended on those dates and the unaudited year to date standalone figures for the nine months ended December 31, 2025 and December 31, 2024 respectively, which were subject to limited review.
3. The statement has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
4. The Company's business activity primarily falls within a single reportable business segment namely "Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".
5. ICRA has assigned a rating of AAA/A1+ on the Company's long term bank facilities (credit facilities)
6. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") - Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

National Stock Exchange of India Limited and BSE Limited have issued letters dated December 23 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Subsequent to the receipt of such letters, the Company has filed an application before the National Company Law Tribunal seeking approval of the scheme.

7. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.
8. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

The Company has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in compensated absence liability by Rs 114 million. Considering the materiality and regulatory driven non-recurring nature of this impact, the Company has presented the same as Exceptional item in the Statement. The Company continues to monitor the finalisation of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

9. The Company had acquired 41,650,638 equity shares aggregating to a 30.58% equity stake held jointly by International Finance Corporation, Washington (IFC) and IFC EAF Apollo Investment Company (IFC EAF) in its subsidiary, Apollo Health and Lifestyle Limited (AHLL), for a total purchase consideration of Rs. 12,540.06 million and the balance shares held by individual shareholders aggregation to 775,744 equity shares for a total consideration of Rs. 186.90 million.

Consequent to the above, AHLL has become a wholly owned subsidiary of the Company.

10. The Board of Directors in their meeting held on May 20, 2026, approved the proposal of merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company.

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

11. During the year ended March 31, 2026, the Group granted Employee Stock Options("ESOPs") and Restricted Stock Units ("RSUs") to eligible employees under the approved employees share-based payment schemes of the Company, pursuant to approvals of the Nomination and Remuneration Committee and the Board during September 2025 and February 2026. During the quarter, the Company granted 251,985 ESOP and 95,757 RSUs to eligible employees. The company has recognised share-based payment expense of Rs. 324 million for the year ended March 31, 2026.
12. The Board declared an interim dividend of Rs.10.00 per share (200%) of face value of Rs.5/- each for the financial year 2025-2026. The record date for the payment was February 16, 2026 and the same was paid on February 27, 2026.
13. The Board recommended a final dividend for the year ended March 31, 2026 of Rs.10/- per equity share (200%) of face value of Rs.5/- each subject to the approval of the members at the forthcoming Annual General Meeting of the Company. The record date for the purpose of the payment of final dividend is August 14, 2026.
14. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai  
Date: May 20, 2026

**Dr. Prathap C Reddy**  
*Executive Chairman*

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

## Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

Statement of consolidated financial results for the three months and the year ended March 31, 2026

(Rs. in Million)

Particulars	Three months ended 31/03/2026	Preceding three months ended 31/12/2025	Corresponding three months ended 31/03/2025	Current year ended 31/03/2026	Previous year ended 31/03/2025
	Refer note 2	Unaudited	Refer note 2	Audited	Audited
<b>1 Income</b>					
(a) Revenue from operations	66,055	64,774	55,922	252,285	217,940
(b) Other income	439	528	611	1,916	2,003
<b>Total Income (a + b)</b>	<b>66,494</b>	<b>65,302</b>	<b>56,533</b>	<b>254,201</b>	<b>219,943</b>
<b>2 Expenses</b>					
(a) Cost of materials consumed	7,774	7,446	6,944	30,408	27,544
(b) Purchases of stock-in-trade	26,131	26,631	22,436	100,564	85,567
(c) Changes in inventories of stock-in-trade	115	(253)	(94)	(216)	(11)
(d) Employee benefits expense	7,720	7,490	7,246	30,003	27,692
(e) Finance costs	1,191	1,126	1,148	4,496	4,585
(f) Depreciation and amortisation expense	2,244	2,192	2,110	8,761	7,575
(g) Other expenses	14,205	13,807	11,693	53,833	46,930
<b>Total expenses</b>	<b>59,380</b>	<b>58,439</b>	<b>51,483</b>	<b>227,849</b>	<b>199,882</b>
<b>3 Profit before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)</b>	<b>7,114</b>	<b>6,863</b>	<b>5,050</b>	<b>26,352</b>	<b>20,061</b>
4 Share of profit/(loss) of associates /joint ventures	101	149	105	449	330
<b>5 Profit before tax and exceptional items (3) + (4)</b>	<b>7,215</b>	<b>7,012</b>	<b>5,155</b>	<b>26,801</b>	<b>20,391</b>
6 Exceptional item (Refer note 9)	-	(192)	-	(192)	-
<b>7 Profit before tax (5) + (6)</b>	<b>7,215</b>	<b>6,820</b>	<b>5,155</b>	<b>26,609</b>	<b>20,391</b>
<b>8 Tax expenses</b>					
Current tax	1,960	1,470	1,190	6,293	5,263
Deferred tax	(258)	187	(180)	289	77
<b>9 Profit after tax for the period/year (7) - (8)</b>	<b>5,513</b>	<b>5,163</b>	<b>4,145</b>	<b>20,027</b>	<b>15,051</b>
<b>10 Other Comprehensive Income</b>					
Items that will not be reclassified to profit or loss					
Remeasurement gains / (losses) on defined benefit plan	(76)	(9)	(36)	(116)	(84)
Equity instruments through other comprehensive income	(10)	-	(2)	735	(2)
Income tax relating to items that will not be reclassified to profit or loss	31	3	9	(64)	17
Items that will be reclassified to profit or loss					
Exchange differences in translating the financial statements of foreign operations	14	4	(1)	29	6
<b>Total other comprehensive income/ (loss)</b>	<b>(41)</b>	<b>(2)</b>	<b>(30)</b>	<b>584</b>	<b>(63)</b>
<b>11 Total comprehensive income for the period/year (9) + (10)</b>	<b>5,472</b>	<b>5,161</b>	<b>4,115</b>	<b>20,611</b>	<b>14,988</b>
<b>Profit for the period/ year attributable to:</b>					
Owners of the parent	5,293	5,023	3,896	19,417	14,459
Non-controlling interest	220	140	249	610	592
<b>Other comprehensive income/ (loss) for the period/ year attributable to:</b>					
Owners of the parent	(47)	(1)	(25)	577	(50)
Non-controlling interest	6	(1)	(5)	7	(13)
<b>Total comprehensive income for the period/ year attributable to:</b>					
Owners of the parent	5,246	5,022	3,871	19,994	14,409
Non-controlling interest	226	139	244	617	579
<b>12 Paid-up equity share capital (Face value Rs.5/- per share)</b>				719	719
Reserves (excluding revaluation reserves)				94,004	81,326
<b>13 Earnings per equity share ('EPS') of Rs.5/- each</b>					
Basic EPS for the period/year (Rs.)	*36.82	*34.94	*27.10	135.04	100.56
Diluted EPS for the period/year (Rs.)	*36.76	*34.94	*27.10	134.94	100.56

\*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD

*Suneeta Reddy*  
SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

## Consolidated balance sheet

(Rs. in Million)

Particulars	As at March 31, 2026	As at March 31, 2025
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	82,586	73,504
(b) Right Of use assets	27,800	24,653
(c) Capital work-in-progress	9,915	7,710
(d) Investment property	22	28
(e) Goodwill	10,323	10,305
(f) Other intangible assets	1,985	1,392
(g) Intangible assets under development	409	1,500
(h) Investments accounted for using the equity method	2,564	2,241
(i) Financial assets		
(i) Investments	9,058	8,304
(ii) Loans	156	272
(iii) Other financial assets	3,530	2,126
(j) Deferred tax assets (net)	141	131
(k) Income tax assets (net)	1,961	2,085
(l) Other non-current assets	2,521	2,034
<b>Total non-current assets</b>	<b>152,971</b>	<b>136,285</b>
<b>Current assets</b>		
(a) Inventories	5,424	4,808
(b) Financial assets		
(i) Investments	10,165	14,323
(ii) Trade receivables	34,849	30,161
(iii) Cash and cash equivalents	8,113	5,781
(iv) Bank balances other than (iii) above	3,055	7,821
(v) Loans	24	51
(vi) Other financial assets	2,086	1,822
(c) Contract assets	1,862	1,722
(d) Other current assets	3,420	3,800
<b>Total current assets</b>	<b>68,998</b>	<b>70,289</b>
<b>Total assets</b>	<b>221,969</b>	<b>206,574</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	719	719
(b) Other equity	94,082	81,404
<b>Equity attributable to owners of the Company</b>	<b>94,801</b>	<b>82,123</b>
Non-controlling interests	4,944	4,406
<b>Total equity</b>	<b>99,745</b>	<b>86,529</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	24,301	44,170
(ii) Lease liabilities	26,703	24,139
(iii) Other financial liabilities	300	313
(b) Provisions	995	886
(c) Deferred tax liabilities (net)	4,982	4,580
(d) Other non-current liabilities	130	168
<b>Total non-current Liabilities</b>	<b>57,411</b>	<b>74,256</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	32,284	8,582
(ii) Lease liabilities	1,641	1,752
(iii) Trade payables		
(a) Total outstanding dues to micro enterprises and small enterprises; and	1,226	808
(b) Total outstanding dues to creditors other than micro enterprises and small enterprises	21,292	21,597
(iv) Other financial liabilities	3,310	8,598
(b) Other current liabilities	3,081	2,643
(c) Provisions	1,953	1,793
(d) Current tax liabilities (net)	26	16
<b>Total current liabilities</b>	<b>64,813</b>	<b>45,789</b>
<b>Total liabilities</b>	<b>122,224</b>	<b>120,045</b>
<b>Total equity and liabilities</b>	<b>221,969</b>	<b>206,574</b>

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

## Consolidated Segment wise revenue, results, segment assets and segment liabilities

(Rs. in Million)

Particulars	Three months ended 31/03/2026	Preceding three months ended 31/12/2025	Corresponding three months ended 31/03/2025	Current year ended 31/03/2026	Previous year ended 31/03/2025
	Refer note 2	Unaudited	Refer note 2	Audited	Audited
<b>1. Segment revenue</b>					
a) Healthcare services	33,337	32,253	28,431	127,501	112,201
b) Retail health and diagnostics	4,895	4,668	3,940	18,653	15,535
c) Digital health and pharmacy distribution	28,482	28,275	23,763	108,081	90,930
d) Others	13	13	12	52	48
<b>SUB - TOTAL</b>	<b>66,727</b>	<b>65,209</b>	<b>56,146</b>	<b>254,287</b>	<b>218,714</b>
Less : Intersegmental revenue	672	435	224	2,002	774
<b>Revenue from operations</b>	<b>66,055</b>	<b>64,774</b>	<b>55,922</b>	<b>252,285</b>	<b>217,940</b>
<b>2. Segment results</b>					
a) Healthcare services	6,146	6,243	5,264	24,303	21,295
b) Retail health & diagnostics	399	117	118	723	300
c) Digital health & pharmacy distribution	1,357	1,080	230	3,987	1,127
d) Others	(37)	21	(25)	(81)	(79)
<b>SUB - TOTAL</b>	<b>7,865</b>	<b>7,461</b>	<b>5,587</b>	<b>28,932</b>	<b>22,643</b>
Less: (i) Finance cost	1,191	1,126	1,148	4,496	4,585
Add: (ii) Other un-allocable income, (net of expenditure)	440	528	611	1,916	2,003
Add: (iii) Share of profit/(loss) of associates / joint ventures	101	149	105	449	330
Add: (iv) Exceptional item	-	(192)	-	(192)	-
<b>Profit before tax</b>	<b>7,215</b>	<b>6,820</b>	<b>5,155</b>	<b>26,609</b>	<b>20,391</b>
<b>3. Capital employed</b>					
<b>a) Healthcare services *</b>					
Segment assets	144,862	136,651	127,403	144,862	127,403
Segment liabilities	(39,357)	(43,559)	(41,107)	(39,357)	(41,107)
<b>b) Retail health and diagnostics</b>					
Segment assets	14,732	13,992	13,277	14,732	13,277
Segment liabilities	(11,436)	(11,636)	(11,005)	(11,436)	(11,005)
<b>c) Digital health and pharmacy distribution</b>					
Segment assets	33,181	31,937	29,629	33,181	29,629
Segment liabilities	(9,466)	(9,425)	(10,206)	(9,466)	(10,206)
<b>d) Others</b>					
Segment assets	257	264	280	257	280
Segment liabilities	(183)	(182)	(179)	(183)	(179)
<b>e) Unallocated</b>					
Segment assets	28,937	41,622	35,984	28,937	35,984
Segment liabilities	(61,782)	(58,655)	(57,547)	(61,782)	(57,547)
<b>Total</b>	<b>99,745</b>	<b>101,009</b>	<b>86,529</b>	<b>99,745</b>	<b>86,529</b>
* Includes Capital employed in various hospital projects under construction	10,324	11,405	9,210	10,324	9,210

FOR APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
**SUNEETA REDDY**  
Managing Director

## Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

### Statement of consolidated cash flows

(Rs. in Million)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
<b>A. Cash flow from Operating Activities</b>		
<b>Profit for the year</b>	<b>20,027</b>	<b>15,051</b>
<b>Adjustments for:</b>		
Depreciation and amortisation expense	8,761	7,575
(Profit)/loss on sale of property, plant & equipment	80	63
Profit on sale of investments (net)	(228)	(132)
Impairment in value of investment	-	20
Share of (profit)/loss of associates	(449)	(330)
Income tax expense	6,582	5,263
Finance costs	4,496	4,585
Interest income	(740)	(924)
Dividend income	(27)	(7)
Expected credit loss on trade receivables	897	629
Provision written back	(10)	(24)
Gain on fair valuation of mutual funds	(619)	(634)
Gain on fair valuation of existing interest of a joint venture pursuant to acquisition of control	(11)	-
Loss /(gain) on fair valuation of equity investments	9	-
Share-based compensation expense	1,589	1,127
Unrealised foreign exchange loss (net)	(2)	1
<b>Operating cash flow before working capital changes</b>	<b>40,355</b>	<b>32,263</b>
<b>(Increase)/decrease in operating assets</b>		
Inventories	(611)	(210)
Trade receivables	(5,533)	(5,642)
Other financial assets	(1,773)	315
Other assets	354	(145)
Contract assets	(140)	(263)
	<b>(7,703)</b>	<b>(5,945)</b>
<b>Increase/(decrease) in operating liabilities</b>		
Trade payables	87	(1,280)
Other financial liabilities	1,356	438
Provisions	121	484
Other liabilities	399	264
	<b>1,963</b>	<b>(94)</b>
<b>Cash generated from operations</b>	<b>34,615</b>	<b>26,224</b>
Net income tax paid	(6,058)	(4,860)
<b>A. Net cash generated from operating activities (A)</b>	<b>28,557</b>	<b>21,364</b>
<b>B. Cash flow from Investing Activities</b>		
Purchase of Property, plant and equipment, capital work-in-progress and intangibles	(19,620)	(17,127)
Proceeds from sale of property, plant and equipment	311	149
Proceeds from /(Investment) in bank deposits	4,787	(3,538)
Purchase of investments in subsidiaries	(13,003)	(24)
Proceeds from sale of non current investments	3	-
Purchase of non current investments	(69)	(7,308)
Purchase of current investments	(17,047)	(24,868)
Proceeds from sale of current investments	22,052	18,151
Loans given	(125)	(291)
Repayments received towards loans	268	84
Interest received	843	844
Dividend Received	118	98
	<b>(21,482)</b>	<b>(33,830)</b>
<b>B. Net cash used in investing activities (B)</b>		
<b>C. Cash flow from financing activities</b>		
Proceeds from issue of equity instruments by a subsidiary company	26	459
Capital contribution from partners	-	10
Proceeds from borrowings	11,149	25,853
Transaction cost incurred on long term borrowings	-	(343)
Repayment of borrowings	(7,340)	(4,422)
Finance costs	(2,776)	(3,018)
Dividend paid on equity shares	(2,876)	(2,732)
Dividend paid by subsidiary to Non Controlling Interest	(52)	(52)
Payment towards lease liability	(2,907)	(2,563)
	<b>(4,776)</b>	<b>13,192</b>
<b>C. Net cash used in financing activities (C)</b>		
<b>Net increase in cash and cash equivalents (A+B+C) = (D)</b>	<b>2,299</b>	<b>726</b>
Cash and cash equivalents at the beginning of the year (E)	5,781	5,055
Add: Cash inflow due to Acquisition of controlling stake in Joint Venture	33	-
Cash and cash equivalents at the end of the year (D) +(E)	8,113	5,781
<b>Cash and cash equivalents comprises of</b>		
- Cash on hand	142	152
- Balance with banks	7,971	5,629
Total cash and cash equivalents at the end of the period	8,113	5,781

APOLLO HOSPITALS ENTERPRISE LTD

  
**SUNEETA REDDY**  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

## NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS:

1. The consolidated financial results ("the Statement") of **Apollo Hospitals Enterprise Limited** ("the Company") for the three months and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 19, 2026 and May 20, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three months ended March 31, 2026 and have expressed an unmodified audit opinion on the consolidated financial results for the year ended March 31, 2026.
2. The consolidated financial results for the three months ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited consolidated figures for the respective years ended on those dates and the unaudited year to date consolidated figures for the nine months ended December 31, 2025 and December 31, 2024 respectively, which were subject to limited review.
3. The statement has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
4. ICRA has assigned a rating of AAA/A1+ on the Company's long term bank facilities (credit facilities)
5. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230-232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

National Stock Exchange of India Limited and BSE Limited have issued letters dated December 23 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Subsequent to the receipt of such letters, the Group has filed an application before the National Company Law Tribunal seeking approval of the scheme.

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

6. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.
7. The Board of Directors in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company.
8. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-compliance with certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated February 9, 2022 seeking explanations as to why the original order should be withdrawn, for which the subsidiary had filed a detailed response explaining that there were no violations of the conditions relating to the allotment of land.

During the current year, the Revenue Department passed an order dated February 13, 2026 cancelling the grant order, alleging that the land had been alienated by the subsidiary on account of share purchase by its holding company. The subsidiary has challenged the said order before the Honourable High Court of Karnataka. The Honourable High Court of Karnataka has granted an interim stay on April 10, 2026 against the cancellation order and has directed the Revenue Department to file its objections.

Based on external legal opinions received, including opinions supporting that transfer of shares does not constitute transfer, alienation or sub-lease of immovable property owned by the subsidiary, the group believes that it has adequate grounds to demonstrate compliance with the applicable conditions of the land grant. Accordingly, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.

9. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

For APOLLO HOSPITALS ENTERPRISE LTD

  
SUNEETA REDDY  
Managing Director

# Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

The Group has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in compensated absence liability by Rs. 192 million. Considering the materiality and regulatory-driven non-recurring nature of this impact, the Group has presented the same as exceptional items in the statement. The Group continues to monitor the finalisation of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

10. During the year ended March 31, 2026, the Group granted Employee Stock Options ("ESOPs") and Restricted Stock Units ("RSUs") to eligible employees under the approved employees share-based payment schemes of the Company, pursuant to approvals of the Nomination and Remuneration Committee and the Board during September 2025 and February 2026. During the quarter, the Group granted 277,234 ESOP and 103,950 RSUs to eligible employees. The Group has recognised share-based payment expense of Rs. 356 million for the year ended March 31, 2026.
11. Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company, has announced plans to combine with Kids Clinic India Limited, which operates under the brand name "Cloudnine", to create one of India's largest maternity and fertility care platform in India. As part of this arrangement, AHLL will divest its stake in its subsidiaries, namely Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited, to Kids Clinic India Limited at an enterprise value of approximately ₹15,500 million, comprising a combination of cash consideration and an equity stake of approximately 9.9% in Kids Clinic India Limited. The transaction has been approved by the Board of Directors of the Company at its meeting held on May 20, 2026 and is subject to receipt of regulatory approvals, including approval of the Competition Commission of India (CCI).
12. The Board declared an interim dividend of Rs.10.00 per share (200%) of face value of Rs.5/- each for the financial year 2025-2026. The record date for the payment was February 16, 2026 and the same was paid on February 27, 2026.
13. The Board recommended a final dividend for the year ended March 31, 2026 of Rs.10/- per equity share (200%) of face value of Rs.5/- each subject to the approval of the members at the forthcoming Annual General Meeting of the Company. The record date for the purpose of the payment of final dividend is August 14, 2026.
14. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai  
Date: May 20, 2026

**Dr. Prathap C Reddy**  
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD

  
**SUNEETA REDDY**  
Managing Director

## INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

#### Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the three months ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the three months and Year Ended March 31, 2026" of **Apollo Hospitals Enterprise Limited** ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

#### (a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

#### (b) Conclusion on Unaudited Standalone Financial Results for the three months ended March 31, 2026

With respect to the Standalone Financial Results for the three months ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the three months ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



### **Management's and Board of Directors' Responsibilities for the Statement**

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial information. This responsibility includes the preparation and presentation of the Standalone Financial Results for the three months and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities**

#### **(a) Audit of the Standalone Financial Results for the year ended March 31, 2026**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Standalone Financial Results for the three months ended March 31, 2026**

We conducted our review of the Standalone Financial Results for the three months ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


**Other Matters**

- The Statement includes the results for the three months ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells LLP**  
*Chartered Accountants*  
(Firm's Registration No. 117366W/W-100018)



Place: Chennai  
Date: May 20, 2026

  
**Nachiappan Subramanian**  
*Partner*  
Membership No. 218727  
UDIN **26218727VUAMAP4666**

## INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

#### Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2026 of **APOLLO HOSPITALS ENTERPRISE LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), and its share of the net profit after tax and other comprehensive income of its joint ventures and associates for the quarter and year ended March 31, 2026, (the "Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

#### (a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of subsidiaries, associates and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2026:

(i) includes the financial results of the following entities:

<b>Name of the Company</b>	<b>Relationship</b>
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited (IHRCL)	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Apollo Nellore Hospital Limited	Subsidiary
Sapient Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Apollomedics International Lifesciences Limited	Subsidiary



**Deloitte  
Haskins & Sells LLP**

<b>Name of the Company</b>	<b>Relationship</b>
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary
Health Axis Private Limited (HAPL)	Subsidiary
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP (w.e.f. 12 July 2024)	Subsidiary
Apollo Healthtech Limited (w.e.f. 10 June 2025)	Subsidiary
Apollo Gleneagles PET-CT Private Limited (w.e.f 30 September 2025)	Subsidiary
Apollo Health Axis Inc (w.e.f 12 November 2025)	Subsidiary of HAPL
Belenus Champion Hospitals Limited (w.e.f 2 February 2026)	Subsidiary of IHRCL
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Care Diagnostics Private Limited (w.e.f. 1 February 2026)	Subsidiary of AHLL
Apollo Dialysis Philippines Inc.	Subsidiary of AHLL
Apollo 24/7 Insurance Services Limited (w.e.f. 3 September 2024)	Subsidiary of AHL
Apollo Consumer Products Limited (w.e.f 31 March 2026)	Subsidiary of AHL
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Apollo CVHF Limited	Subsidiary of AHIL
Baalayam Healthcare Private Limited	Subsidiary of KFHS
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollo Fertility Centre Private Limited (Formerly known as Surya Fertility Centre Private Limited)	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited (Formerly known as Kshema Healthcare Private Limited)	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Apollo Pharma Products Pvt Limited	Subsidiary of AMPL
ApoKos Rehab Private Limited	Joint venture



<b>Name of the Company</b>	<b>Relationship</b>
Nexify Health Private Limited (w.e.f. 30 September 2024)	Joint venture of HAPL

- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2026.

**(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026**

With respect to the Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026**

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associates and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

**Emphasis of Matter**

We draw attention to Note 8 of the Consolidated financial results in respect of proceedings initiated against the company's subsidiary, Imperial Hospital and Research Centre Limited, by the Government of Karnataka.

Our report is not modified in respect of this matter.



**Management's and Board of Directors' Responsibilities for the Statement**

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associates and joint ventures in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for overseeing the financial reporting process of the Group and of its associates and joint ventures.

**Auditor's Responsibilities**

**(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.



## **Deloitte Haskins & Sells LLP**

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group and its associates and joint ventures to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.



We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026**

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

**Other Matters**

- The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements of 34 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 37,356 million as at March 31, 2026 and total revenues of Rs. 5,223 million and Rs. 19,940 million for the quarter and year ended March 31, 2026 respectively, total net profit after tax of Rs. 393 million and Rs. 1,335 million for the quarter and year ended March 31, 2026 respectively and total comprehensive income (net) of Rs. 408 million and Rs. 1,344 million for the quarter and year ended March 31, 2026 respectively and net cash flows of Rs. 1,251 million for the year ended March 31, 2026, as considered in the Statement. The consolidated financial results also includes the Group's share of total net profit after tax of Rs. 98 million and Rs. 425 million for the quarter and year ended March 31, 2026 respectively and total comprehensive income (net) of Rs. 95 million and Rs. 427 million for the quarter and year ended March 31, 2026 respectively, as considered in the Statement, in respect of 7 associates (including 3 subsidiaries of 1 associate) and 1 joint ventures whose financial statements have not been audited by us.



# Deloitte Haskins & Sells LLP

These financial statements have been audited, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

- The consolidated financial results includes the unaudited financial statements of 2 subsidiary whose financial statements reflect total assets of Rs. 1 million as at March 31, 2026 and total revenues of Rs. Nil and Rs. Nil for the quarter and year ended March 31, 2026 respectively, total net Profit after tax of Rs. Nil and Rs. Nil for the quarter and year ended March 31, 2026 respectively and total comprehensive loss of Rs. Nil and Rs. Nil for the quarter and year ended March 31, 2026 respectively and net cash flows of Rs. Nil for the year ended March 31, 2026 as considered in the Statement. These financial statements are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial information certified by the Board of the Directors.

for **Deloitte Haskins & Sells LLP**

*Chartered Accountants*

(Firm's Registration No. 117366W/W-100018)

Place: Chennai  
Date: May 20, 2026



  
**Nachiappan Subramanian**  
*Partner*

Membership No. 218727  
UDIN: 26218727OCEYWE6108

PRESS RELEASE

## Apollo Hospitals Announces Strong Q4FY26 Performance and Key Strategic Milestones

- Apollo Hospitals reported strong growth in revenue and EBITDA across all three business verticals, as well as at the consolidated level, reflecting sustained operational momentum and resilient demand across healthcare services.
- ICRA assigned Apollo Hospitals the highest credit rating of AAA for both long-term and short-term borrowings, marking a first for an Indian hospital services company. The rating reflects Apollo's strong financial risk profile, diversified scale of operations, healthy profitability metrics, and robust liquidity position.
- Apollo Cradle and Fertility and Cloudnine combine to create one of India's largest integrated Maternity and Fertility care Platforms. AHLL's Mother & Child and Fertility Businesses Valued at INR 1,550 Crores through combination of Cash and 9.9% Equity Stake in the Combined Entity. Apollo Health and Lifestyle to become the Largest Non-Financial Shareholder in the Combined Platform
- Apollo's expansion plans remain firmly on track, with upcoming hospitals in the Financial District, Hyderabad, and Sonarpur, Kolkata. The Group also successfully launched four hospitals over the past six months.
- The Board has recommended a final dividend of ₹10 per equity share for FY26.
- The Company achieved significant clinical excellence milestones during the quarter, supported by improved performance in CONGO-T specialties and growth in high-complexity procedures.
- The International Patient Services division continued to witness increasing traction, reinforcing Apollo's position as a preferred global healthcare destination.
- Apollo further strengthened its payor mix through sustained consumer preference and deeper engagement with health insurance partners.

## Key Clinical Highlights

- Apollo Hospitals, Chennai, successfully facilitated three coordinated organ transfers within a single day using dedicated road and metro green corridors to ensure minimal ischemic times. The organs were donated by a 17-year-old donor and transported from Madurai.
- Apollo Children's Hospitals, Chennai, performed Tamil Nadu's first Cochlear Nucleus Nexa Implant surgery on a nine-year-old girl from Bangladesh who was born with severe hearing loss.
- Indraprastha Apollo Hospitals, Delhi, successfully performed a total hip replacement on a 14-year-old patient suffering from severe complications related to sickle cell disease.

# Apollo Hospitals Q4FY26 Results



## Q4FY26 Consolidated Results

Q4 Consolidated Revenue grew 18% YoY to Rs. 6,605 Crore

Q4 Consolidated EBITDA grew 31% YoY to Rs. 1,011 Crore

Q4 Consolidated PAT grew 36% YoY to Rs. 529 Crore

## YTD MAR FY26 Consolidated Results

YTD MAR FY26 Consolidated Revenue grew 16% YoY to Rs. 25,229 Crore

YTD MAR FY26 Consolidated EBITDA grew 25% YoY to Rs. 3,769 Crore

YTD MAR FY26 Consolidated PAT grew 34% YoY to Rs. 1,942 Crore

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said:

“FY26 marks another important milestone in Apollo’s journey of building a healthcare institution anchored in clinical excellence, patient-centric care, and responsible growth. Our revenue of ₹25,229 crore reflects the enduring trust that patients and their families continue to place in Apollo. Across our core segments — Healthcare Services, Diagnostics and Retail Health, and Digital and Pharmacy — we delivered steady, broad-based growth, supported by the strength of our integrated healthcare model.

Our expansion strategy continues to be guided by India’s long-term healthcare needs. During the year, we strengthened our footprint through new facility launches and continued progress on expansion projects across key cities. At the same time, we remain deeply committed to improving access to high-quality healthcare in Tier 2 and Tier 3 markets. This is not only a strategic priority, but also a responsibility — to bring advanced healthcare closer to underserved communities while maintaining the highest standards of care.

I am particularly pleased that Apollo HealthCo reported its first full year of profitability while continuing to scale its pharmacy and digital health operations. This reflects our commitment to building a more connected and accessible healthcare ecosystem, where care increasingly extends beyond hospitals into homes and communities.

The proposed demerger of our pharmacy and digital health businesses is a strategic step towards enabling sharper focus, accelerated growth, and long-term value creation. Subject to the completion of regulatory and stakeholder processes, the new entity is progressing towards a potential listing by Q4 FY27.

During the latter part of the year, we engaged with global healthcare leaders through our International Health Dialogues initiative. These engagements continue to strengthen our understanding of emerging models of care and reinforce Apollo’s commitment to combining global best practices with solutions tailored to India’s unique healthcare needs.

India’s healthcare landscape is undergoing rapid transformation. The Union Budget’s emphasis on regional medical hubs through public-private partnerships, along with India’s growing stature as a global Medical Value Travel destination, presents significant opportunities for Apollo. International patient revenues maintained strong momentum during FY26, supported by deeper partnerships with governments, embassies, and healthcare information centres across Africa, the Middle East, Bangladesh, and Southeast Asia.

Innovation will remain central to our growth strategy. Our investments in technology are focused on improving clinical outcomes, supporting our doctors, and enhancing patient experience. We continue to strengthen specialised care across oncology, neurosciences, transplantation, and emergency care, reflecting our commitment to advancing healthcare standards in India.

Looking ahead, our priorities remain clear — disciplined operationalisation of new capacities, sustained focus on our core hospital business, and continued momentum across emerging businesses. Above all, we remain committed to expanding access to quality healthcare and contributing meaningfully to the strengthening of India’s healthcare infrastructure.”

## Financial Performance – Q4FY26

### **Consolidated Q4FY26 Performance**

- Revenue at Rs. 6,605 crore vs Rs. 5,592 crore in Q4FY25; growth of 18% YoY
- EBITDA at Rs. 1,011 crore vs Rs. 770 crore in Q4FY25. This is after Apollo 24/7 cost of Rs. 96 crore in the quarter (incl. Rs. 23 crore non-cash ESOP charge) vs Rs. 160 crore in Q4FY25.
- Reported PAT at Rs. 529 crore vs Rs. 390 crore in Q4FY25
- Diluted EPS of Rs. 36.76 per share in Q4FY26 (not annualized)
- GMV of Apollo 24/7 at Rs. 528 Crore

### **Healthcare service Q4FY26 Performance**

- Revenue at Rs. 3,268 crore vs Rs. 2,822 crore in Q4FY25; growth of 16% YoY
- EBITDA grew 14% at Rs. 781 crore vs Rs. 686 crore in Q4FY25; Margins at 23.9% in Q4FY26
- PAT stood at Rs. 412 crore vs Rs. 385 crore in Q4FY25, up 7% YoY

### **Apollo Health and Lifestyle Limited Q4FY26 Performance**

- Revenue at Rs. 489 crore vs Rs. 394 crore in Q4FY25; growth of 24% YoY
- EBITDA grew 58% at Rs. 75 crore vs Rs. 47 crore in Q4FY25; Margins at 15.3% in Q4FY26
- PAT Profit of Rs. 10 crore vs loss of Rs. 4 crore in Q4FY25

### **Apollo HealthCo Q4FY26 Performance**

- Revenue at Rs. 2,848 crore vs Rs. 2,376 crore in Q4FY25; growth of 20% YoY
- EBITDA at Rs. 156 crore vs Rs. 36 crore in Q4FY25; Margins at 5.5% in Q4FY26
- PAT stood at Rs. 107 crore vs Rs. 9 crore in Q4FY25

## Financial Performance – FY26

### Consolidated FY26 Performance

- Revenue at Rs. 25,229 crore vs Rs. 21,794 crore in FY25; growth of 16% YoY
- EBITDA at Rs. 3,769 crore vs Rs. 3,022 crore in FY25. This is after Apollo 24/7 cost of Rs. 467 crore in FY26 (incl. Rs. 118 crore non-cash ESOP charge) vs Rs. 586 crore in FY25
- Reported PAT at Rs. 1,942 crore vs Rs. 1,446 crore in FY25
- Diluted EPS of Rs. 134.95 per share in FY26
- GMV of Apollo 24/7 at Rs. 2037 Crore

### Healthcare service FY26 Performance

- Revenue at Rs. 12,555 crore vs Rs. 11,147 crore in FY25; growth of 13% YoY
- EBITDA grew 14% at Rs. 3,069 crore vs Rs. 2,701 crore in FY25; Margins at 24.4% in FY26
- PAT stood at Rs. 1,628 crore vs Rs. 1,426 crore in FY25, up 14% YoY

### Apollo Health and Lifestyle Limited FY26 Performance

- Revenue at Rs. 1,865 crore vs Rs. 1,554 crore in FY25; growth of 20% YoY
- EBITDA grew 38% at Rs. 213 crore vs Rs. 154 crore in FY25; Margins at 11.4% in FY26
- PAT loss of Rs. 10 crore vs loss of Rs. 27 crore in FY25

### Apollo HealthCo FY26 Performance

- Revenue at Rs. 10,808 crore vs Rs. 9,093 crore in FY25; growth of 19% YoY
- EBITDA at Rs. 488 crore vs Rs. 168 crore in FY25; Margins at 4.5% in FY26
- PAT stood at Rs. 324 crore vs Rs. 47 crore in FY25

## Q4 FY26 Segment-wise Performance Update

### Healthcare Services (Hospitals)

As on March 31, 2026, Apollo Hospitals had 8,131 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 68% in Q4FY26 vs 67% in the same period in the previous year.

Consolidated Revenue of the healthcare services division grew 16% to Rs.3,268 crore in Q4FY26 compared to Rs.2,822 crore in Q4FY25.

EBITDA (Post Ind AS 116) was at Rs. 781 crore in Q4FY26 compared to Rs. 686 crore in Q4FY25. EBITDA, higher by 14% YoY.

Revenue in the Tamil Nadu cluster grew 14%, IP Volumes grew 5%. ARPP grew 9% to Rs. 2,14,598. Overall occupancy in the cluster was 1,348 beds (68% occupancy) as compared to 1,337 beds (65% occupancy) in the previous year.

In AP Telangana region, Revenue grew 21%, IP volumes grew 20%. ARPP grew 2% to Rs. 1,92,387 Occupancy in the cluster was 882 beds (66% occupancy) as compared to 788 beds (64% occupancy) in the previous year.

In Karnataka region, Revenue grew 17%, IP volumes grew 7%. ARPP grew 11% to Rs. 1,95,083 Occupancy in the cluster was 560 beds (72% occupancy) as compared to 538 beds (70% occupancy) in the previous year.

In Eastern region, Revenue grew 16%, IP volumes grew 7%. ARPP grew 10% to Rs. 1,60,304. Occupancy in the cluster was 1,434 beds (77% occupancy) as compared to 1,367 beds (73% occupancy) in the previous year.

In Western region, Revenue grew 19%, IP volumes degrew 4%. ARPP grew 15% to Rs. 1,75,751. Occupancy in the cluster was 513 beds (56% occupancy) as compared to 491 beds (56% occupancy) in the previous year.

In Northern region, Revenue grew 11%, IP volumes grew 1%. ARPP grew 10% to Rs.1,77,543 Occupancy in the cluster was 814 beds (66% occupancy) as compared to 844 beds (70% occupancy) in the previous year.

### Apollo Health and Lifestyle Limited: Diagnostics and Retail Healthcare

- AHLL Gross Revenue at Rs. 489 crore; up 24% YoY
- Diagnostics Revenue stood at Rs. 194 crore, Primary Care at Rs. 130 crore, Specialty Care at Rs.189 crore.

## Apollo HealthCo: Digital Healthcare and Omni-channel Pharmacy platform

- Overall Health Co Revenue were at Rs. 2,848 crore vs Rs. 2,376 crore in Q4FY25 representing 20% YoY growth.
- Offline Pharmacy distribution Revenue were at Rs. 2,518 crore vs Rs. 2,084 crore in Q4FY25 while Revenue from Digital platform were at Rs. 330 crore vs Rs. 292 crore in Q4FY25.
- 176 net new stores were opened in this quarter, taking the total number to 7,289 stores.
- GMV of Apollo 24/7 at Rs. 528 crore in Q4 FY26, growth of 20% over Q4FY25.
- Avg Q4FY26 run rate of 69K/day order across Pharma, Diagnostics Consultations (excluding IP/OP referrals) compared to 63K/day in Q4FY25.

## CLINICAL EXCELLENCE HIGHLIGHTS

### Tamilnadu

#### Apollo Hospitals, Greams Road, Chennai

**High-risk TAVI:** An 85-year-old man with severe aortic stenosis and multiple comorbidities survived a complex valve replacement, regaining heart function despite critical risk.

**Robotic Mesh Erosion Surgery:** A 60-year-old man with rare intestinal mesh erosion was treated in a single robotic procedure, avoiding stoma and enabling rapid recovery.

**Organ Transplants Milestone:** Three transplants (lung, bilateral lung, heart) were coordinated in one day via green corridors, saving three lives in a record demonstration of Apollo's logistics and surgical excellence.

#### Apollo Hospitals, Teynampet & Vanagaram, Chennai

**Advanced Endoscopic Submucosal Dissection:** An 80-year-old woman's large adenoma was removed minimally invasively, first in Tamil Nadu.

**Renal Denervation + Angioplasty:** A 70-year-old man with resistant hypertension achieved control after combined intervention.

**TAVI for Severe Dysfunction:** A 64-year-old man with bicuspid valve disease and EF 18% survived transcatheter valve replacement

**Neurovascular Coil Embolization:** A 49-year-old man with ruptured aneurysm was stabilised through endovascular repair.

#### Apollo Children's Hospitals, Chennai

**Cochlear Nucleus Nexa Implant:** A 9-year-old girl from Bangladesh, born with severe hearing loss, underwent Tamil Nadu's first Nexa implant surgery. The procedure restored her ability to hear and speak.

**Carotico-cavernous Fistula:** A 45-year-old man with vision loss recovered after targeted embolization.

**Abernethy Malformation:** A 13-year-old girl from Theni with a rare congenital anomaly had normal blood flow restored, enabling recovery.

## Karnataka

### Apollo Hospitals, BG Road, Bangalore

**Mucous Membrane Graft (MMG):** A high-risk Stevens–Johnson Syndrome patient regained healthy eyelid function through grafting lip mucosa, preventing blindness and restoring comfort.

**Corneal Transplant:** A 30-year-old factory worker blinded by molten aluminium injury had his vision restored, enabling him to return to independent life.

**Robotic Knee Replacement:** A 17-year-old boy with advanced osteonecrosis, unable to walk, regained mobility and quality of life through robotic precision surgery.

### Apollo Hospitals, Jayanagar, Bangalore

**WEB Flow Diverter (Woven EndoBridge):** Karnataka's first minimally invasive aneurysm repair saved a patient with a complex brain aneurysm.

**Hot AXIOS Stent:** A 50-year-old woman with pancreatic pseudocyst achieved immediate drainage and relief through advanced endoscopy.

## Apollo Hospitals, Mysore

**HIPEC for Ovarian Cancer:** A 66-year-old woman with Stage IIIC carcinoma underwent cytoreductive surgery with heated chemotherapy, extending survival prospects.

**Retroperitoneal Sarcoma Excision:** A complex tumour involving kidney and arteries was removed successfully, preserving life.

**Sigmoid Volvulus in Pregnancy:** A 25-year-old pregnant woman was treated laparoscopically, safeguarding both mother and fetus.

**Robotic Completion Cholecystectomy:** A 50-year-old hypertensive woman with distorted anatomy was treated

## Telangana, Apollo Hospitals, Hyderabad (Jubilee Hills)

**RAFAELO Procedure:** Introduced painless haemorrhoid treatment, removing fear of surgery and recovery for patients.

**Wernicke's Encephalopathy:** A 60-year-old man recovered rapidly from confusion and vision loss after timely thiamine therapy.

**Same-day Deep Brain Stimulation:** A Parkinson's patient received lead and implant in one session, reducing hospital stay and accelerating recovery.

**Milestone: Jubilee Hills crossed 2,000 robotic surgeries, a record across Telangana and Andhra Pradesh.**

**Andhra Pradesh, Apollo Hospitals, Vizag**

**First David Procedure in Vizag:** A 43-year-old man with Type A aortic dissection underwent valve-sparing root surgery, preserving his native valve and saving his life.

**Delhi / NCR, Indraprastha Apollo Hospitals, Delhi**

**Cryoablation for Breast Tumour:** A 77-year-old woman with a tumour near her heart was treated safely under local anaesthesia, discharged within hours.

**Hip Replacement in Sickle Cell Disease:** A 14-year-old girl crippled by sickle cell complications regained mobility and independence.

**Cardiac Arrest Revival:** A 61-year-old Zambian patient collapsed in OPD; immediate CPR and defibrillation saved his life, followed by AICD implantation for long-term safety.

**Leadless Pacemaker:** India's first implantation through a prosthetic tricuspid valve offered a safer option for complex cardiac patients.

**Kidney Transplant for Rare TMA:** A 36-year-old man, rejected by multiple hospitals, received a successful transplant despite genetic clotting disorder.

**Maharashtra**

**Apollo Hospitals, Navi Mumbai**

**LAAC Procedure:** A 69-year-old man with atrial fibrillation avoided stroke risk without long-term anticoagulants.

**SMA Thrombosis/Dissection:** A 47-year-old man survived a vascular emergency through urgent endovascular repair.

**Robotic Hysterectomy:** A 37-year-old woman with Glanzmann's Thrombasthenia avoided life-threatening bleeding through robotic precision.

**Complex Aortic Aneurysm Repair:** An 87-year-old man with imminent rupture was saved by endovascular exclusion.

**Apollo Hospitals, Nashik**

**Female Urethral Stricture:** A 60-year-old woman regained normal urinary function after buccal mucosal graft surgery.

**TAVI:** A 69-year-old man with severe stenosis avoided open surgery through transcatheter valve replacement.

**Uttar Pradesh, Apollo Medics Hospitals, Lucknow**

**Catheter-directed Thrombolysis in Child:** A 2.5-year-old girl with CVST survived a rare intracranial intervention, regaining neurological function.

*First Minimally Invasive Atrial Septal Defect (ASD) closure in the state:* Uttar Pradesh's first keyhole heart defect closure avoided major surgery and reduced trauma.

**Rare Pediatric Stroke:** Another 2.5-year-old child with multiple brain infarcts recovered after direct intracranial thrombolysis, a life-saving rarity.

**Assam, Apollo Excelcare Hospitals, Guwahati**

**POEM Procedure:** Northeast India's first minimally invasive Peroral Endoscopic Myotomy surgery relieved a patient's chronic swallowing disorder, setting a new regional benchmark.

**Rare GU Lymphoma:** An elderly man misdiagnosed with carcinoma was correctly identified with aggressive lymphoma; chemotherapy achieved complete remission.

**High-risk CABG:** A 61-year-old man with triple vessel disease and pneumonia survived off-pump bypass surgery, highlighting Apollo's multidisciplinary critical care.

## NEW LAUNCHES, INITIATIVES AND PARTNERSHIPS

1. International Health Dialogue (IHD) 2026, held in Hyderabad, reinforced Apollo Hospitals' leadership in shaping the future of healthcare by convening over 5,000+ delegates and 400+ global speakers, including policymakers, clinicians, and industry leaders, across a truly international platform. The two-day forum, which generated 1.2 million+ digital engagements, brought together stakeholders from 34 international hospitals, 221 national organisations, 62 academic institutions, and 32 government bodies, underscoring its scale and global relevance.

Anchored under the theme "Global Voices, One Vision," the 13th edition marked a shift from dialogue to action, integrating key platforms such as IPSC, HOPE, CLINOVATE, and THIT to drive advancements in patient safety, clinical excellence, and digital health. A key highlight was Apollo's strategic collaboration with Roche Diagnostics India to advance digital innovation in clinical care, alongside initiatives focused on AI, healthtech, and system-wide transformation. Collectively, IHD 2026 strengthened Apollo's positioning as a catalyst for global healthcare collaboration, innovation, and the advancement of safer, more resilient, and patient-centric healthcare systems.

2. Apollo Hospitals Financial District was commissioned in April 2026. The 400-bedded, next-generation smart hospital located in Hyderabad is a part of Apollo's pan-India network delivering complex and advanced care at scale. The hospital was inaugurated by the Hon'ble Chief Minister of Telangana, Revanth Reddy.
3. Apollo has launched in Sonarpur, Kolkata with 270 total beds.

4. "From Grey Zones to Black & White in the Management of Breast Cancer." The academic initiative emphasised Precision, Progress, and Personalisation, featuring focused sessions on image guided precise tumour mapping, Tumor Cartography, individualised precision oncology, advanced oncoplastic techniques—including Breast Reconstruction and clear de-escalation strategies in post NAST axilla. The academic initiative aimed to bring together leading oncologists, clinicians, and healthcare professionals to discuss advancements, innovations, and multidisciplinary approaches in Breast cancer care.
5. Launch of MRI VABB at Apollo Athenaa in Jan 26, to bring in a transformative leap in early and accurate diagnosis of breast cancer and non-palpable breast cancers, particularly in younger women and those with dense breast tissue.
6. In line with World Cancer Day observed on 4th February this year, Apollo Cancer Centre launched "Zero to Hero" campaign to encourage early detection of cancer and improve survival and recovery.

## AWARDS AND ACCOLADES

### Tamil Nadu

#### Apollo Specialty Hospital, Vanagaram

1. CAHO Excellence Award, 2nd position in Endosafe certification,
2. Apollo Clinical Excellence Award Group B

#### Apollo Women's Hospital

1. Apollo Clinical Excellence Award Winner - Group C category
2. Nursing Excellence Award Winner in Group C category

#### Apollo First Med Hospitals

1. Service Excellence Pioneer Award – Group C Category
2. Operation Championship Award in Feb and March 2026

#### Apollo Reach Hospitals, Karaikudi

1. Operational Excellence Award Winner in Group C Category
2. Nursing Excellence Award Winner in Group C category
3. Service Excellence Award Winner in Group C Category

### Apollo Proton Cancer Centre

1. CAHO Excellence Award - 1st position in Endosafe certification

### Telangana

#### Apollo Health City, Jubilee Hills

1. Excellence in Medical Education (Excellence in Clinical Training) 2025, honoured at AHPI Global Conclave on 23rd Jan 2026, Taj Lands End, Mumbai.
2. Most preferred Medical Tourism Hospital in India 2025, honoured at 16th MT India Healthcare Awards 2026, Pragati Maidan (Bharat Mandapam), New Delhi.
3. Endoscopy Safety Audit and Facility Evaluation (ENDO-SAFE) - Southern Region, honoured at CAHOCON 2026, 10-12 April 2026 at the Chennai Trade Centre, Chennai, India.

#### Apollo Hospitals. Karimnagar

1. Super star Award for Operational Excellence- Jan 2026.
2. Pro Health special Recognition for excellence of Lab services for low TAT across the peer group unit in Q3-FY-26, Group C winner Award.

### Gujarat, Apollo Hospitals, Ahmedabad

1. AHPI Award for Excellence in Nursing Practices - Jan'26
2. Sandesh - Healthcare Excellence Award -2026 Gold Category
3. CAHO ACE CSSD Certificate & Award
4. CAHO ENDOSAFE 1st place in North Region

### Uttar Pradesh, Apollo Medics Super Speciality Hospitals, Lucknow

1. Prof. Dr. Amit Gupta received Lifetime Achievement award from North Zone Indian Society of Nephrology

### Odisha, Apollo Hospitals, Bhubaneswar

1. Best Patient Centric Hospital at "OTV Business Award"
2. Best Healthcare Service Award at "SAMAYA CONCLAVE 2026"
3. CAHO - Endosafe Certification for Center of Excellence

**West Bengal, Apollo Multispeciality Hospitals, Kolkata**

1. CAHO - Endosafe (Winner in Eastern Region)
2. Elsevier RAISE Awards - Elsevier RAISE (Responsible AI for Strengthening Excellence in Healthcare) Award

**Assam, Apollo Hospitals Guwahati**

1. CAHO - Endosafe Certification
2. Hospital of the year by News 18 -24-03-2026
3. Quality Certificate by Infusion Nurse Society, India

**Kerala, Apollo Adlux Hospital, Kochi**

1. National Safety Council Award for Hospitals - 2026
2. 'Happy Employer Brands - 2026' by the World HRD Congress

## **CORPORATE SOCIAL RESPONSIBILITY**

Last year, the CSR initiatives of Apollo Health Enterprise Limited have impacted 10.83 lakh people across the country, including 5,20,772 individuals through Apollo Foundation - Total Health and 5,63,657 individuals through the Billion Hearts Beating Foundation, collectively strengthening large-scale community outreach, preventive healthcare delivery, and integrated social development across regions.

## About Apollo

*Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform with over 10,900 beds across 78 hospitals, 7,200+ pharmacies, 300+ clinics, 2,500 diagnostic centres. It is one of the world's leading cardiac centres, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.*

For further details, log onto: [www.apollohospitals.com](http://www.apollohospitals.com)

For further information, please contact:

For Media / Investors

R Krishnakumar  
Apollo Hospitals Enterprise Ltd.  
[Krishnakumar\\_r@apollohospitals.com](mailto:Krishnakumar_r@apollohospitals.com)  
+91 44 2829 7840

Mayank Vaswani  
CDR India  
[mayank@cdr-india.com](mailto:mayank@cdr-india.com)  
+91 22 6645 1230

## Disclaimer

*Some of the statements in this document that are not historical facts are forward looking statements. These forward-looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.*

*These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.*

*Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.*

**Annexure-2 & 3**

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

<b>Particulars</b>	<b>Dr. Prathap C Reddy</b>	<b>Ms. Rama Bijapurkar</b>
Reason for change viz., appointment, resignation, removal or otherwise	<p>The existing term of Dr. Prathap C Reddy as whole time director designated as Executive Chairman is due for renewal on 24<sup>th</sup> June 2026.</p> <p>Based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors at its meeting held today i.e., May 20, 2026 has approved the re-appointment of Dr. Prathap C Reddy as whole time director designated as Executive Chairman for a further period of two years w.e.f. 25<sup>th</sup> June 2026 and recommended to the member's approval.</p>	<p>Ms. Rama Bijapurkar current tenure (1st term) as an Independent Director of the Company expires on November 12, 2021.</p> <p>Based on the recommendation of the Nomination and Remuneration Committee of the Company, the Board of Directors at its meeting held today i.e., May 20, 2026 has approved the re-appointment of Ms. Rama Bijapurkar, as an Independent Director for a second term of five consecutive years from November 12, 2026 to November 11, 2031 for a further period of 5 years, subject to the approval of the members at the general meeting</p>
Date of Appointment/cessation & term of appointment	Dr. Prathap C Reddy has been reappointed as Executive Chairman of the Company for a further period of two years w.e.f. 25 <sup>th</sup> June 2026 subject to member's approval in the ensuing annual general meeting.	Ms. Rama Bijapurkar has been re-appointed with effect from November 12, 2021 for a period of five years i.e., w.e.f. November 12, 2021 to November 11, 2031, subject to the approval of members.
Brief Profile (in case of appointment)	Annexure Enclosed	Annexure Enclosed
Relationship (in case of appointment)	Dr. Prathap C Reddy is father of Ms. Preetha Reddy Executive Vice Chairperson, Ms. Suneeta Reddy, Managing Director, Ms. Shobana Kamineni, Non-Executive Director and Ms. Sangita Reddy, Joint Managing Director.	Ms. Rama Bijapurkar is not related to any Directors or Key Managerial Personnel of the Company.



<p>Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018 /02 dated June 20, 2018 issued by the BSE and NSE, respectively</p>	<p>Dr. Prathap C Reddy is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.</p>	<p>Ms. Rama Bijapurkar is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.</p>
---	---	---



## Profiles

### Dr. Prathap C Reddy

Dr. Prathap C Reddy, Founder-Chairman of the Apollo Hospitals Group, is the visionary architect of modern Indian healthcare. He is best described as a compassionate humanitarian who dedicated his life to bringing world-class healthcare within the economic and geographic reach of millions.


In 1983, Dr. Reddy embarked on an extraordinary journey by establishing Apollo Hospitals, which not only revolutionized healthcare in India but also pioneered the private healthcare industry in India. The Apollo model of care inspired many, and at present, over 300 other large, high-quality hospitals have elevated the quality of care in India, making it available at a tenth of the international cost and changing the way people in the country live and access healthcare.

To this day, despite his senior age, Dr. Reddy works tirelessly for more than 20 hours every single day to realize his vision of making world-class healthcare accessible to all. His vision was not limited to hospitals, but aimed at creating an integrated ecosystem of care. Under his leadership, the Apollo Hospitals Group has established around 7000 pharmacies, over 2000 retail touchpoints, and well over 25 million registered users on the digital platform Apollo 24/7.

Driven by a profound sense of social responsibility, Dr. Reddy's vision extends far beyond the boundaries of urban centers. He harnessed technology to provide high-quality medical care even to the remotest corners of the country, as illustrated by the tremendous success of telemedicine in India. Above all, Dr. Reddy gave hope to every citizen and patients in over 150 countries around the world, where none existed before.

Dr. Reddy has been a staunch advocate for mandatory health insurance, firmly believing it is crucial for the nation's wellbeing. His pioneering Re.1-a-day insurance project, initially introduced in his native village, set the stage for the Government of India's Universal Health Insurance program.

A thinker far ahead of his time, in the mid-70s, Dr. Reddy introduced the Master Health Check in India and continues to passionately champion preventive healthcare. Over 30 million health checks have been performed by the Apollo Hospitals Group to date, and given the burgeoning prevalence of non-communicable diseases, the importance of this work cannot be underestimated. His keen commitment to battling disease is evident in his



leadership of the Billion Hearts Beating Foundation, which encouraged Indians to prioritize heart health.

In the realm of policy and thought leadership, Dr. Reddy has played pivotal roles in establishing various healthcare organizations and committees, and has been the prime shaper of healthcare policy and delivery in India. He has been instrumental in founding NATHEALTH, a powerful forum fostering a shift in mindsets and policies for the benefit of health across the nation, and GAPIO, the Global Association of Physicians of Indian Origin, a network of highly qualified physicians from around the world.

Recognized and revered globally, Dr. Prathap C Reddy was honored with the 'Padma Vibhushan,' India's second-highest civilian award, for his unwavering pursuit of excellence in healthcare. His biography, "Healer: Dr Prathap Chandra Reddy and the Transformation of India," serves as a testament to his incredible journey of healing and caring, inspiring generations to come.

A dedicated philanthropist, Dr. Reddy introduced social initiatives that helped transcend barriers, and a notable example is the Save a Child's Heart Initiative, which is addressing the widespread issue of congenital heart disease in India.

In addition, he has always been passionate about a holistic approach to community development, as exemplified by the Total Health Foundation that aims to uplift individuals physically, mentally, emotionally, financially, and spiritually, building inclusive communities. An innovative population health model, the Total Health program in Dr. Reddy's native district, Aragonda in southern India, has achieved dramatic results, which have been published by prestigious institutions like the Harvard School of Public Health. Now, Aragonda is truly, in spirit, a Blue Zone.

Throughout his work over the last 40 years in Indian healthcare, Dr. Reddy has been anchored in a strong sense of purpose – health and happiness for all. In the 40th year of the founding of Apollo Hospitals, the Apollo family re-dedicated itself to this purpose, aiming to transcend barriers of geography, capability, or technology to create a lasting, sustainable impact.

Dr. Prathap C Reddy, Founder-Chairman of the Apollo Hospitals Group, is the visionary architect of modern Indian healthcare. He is best described as a compassionate humanitarian who dedicated his life to bringing world-class healthcare within the economic and geographic reach of millions.



Dr. Prathap C Reddy was conferred the 'Padma Vibhushan,' the second highest civilian award by the Government of India in acknowledgment of his tireless pursuit of excellence in healthcare.

**Ms. Rama Bijapurkar**

Ms. Rama Bijapurkar is a recognised thought leader on business-market strategy and India's consumer economy. Her consulting, research and teaching work of four decades has been in and around the areas of improving customer centricity in business strategy and public policy.

Ms. Bijapurkar is amongst India's most experienced independent board directors and has served on the boards of several of India's blue-chip companies across a range of sectors including financial services, IT, energy, consumer packaged goods etc and on advisory groups and governing councils of premier academic institutions, regulatory and quasi regulatory bodies and policy research institutions. She is also a visiting faculty at the Indian Institute of Management, Ahmedabad.

Ms. Bijapurkar has been a dominant voice on India's business and policy issues in her area of work through her media columns, public speaking and her hallmark books on Consumer India and India's consumer economy are widely acclaimed both India and outside.

Ms. Bijapurkar holds a BSc (Hons) degree in Physics from Delhi University and a post graduate diploma in management from the Indian Institute of Management, Ahmedabad. Her over four decades of work experience in strategy consulting and market research includes her own consulting practice, and employment with McKinsey & Company, MARG (now Nielsen India) and Mode Services (now TNS India).



## Annexure-4

Details as required under Regulation 30 of Listing Regulations read with SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No	Particulars	Details									
1.	Name of the target entities, details in brief such as size, turnover etc.	<p>Apollo Specialty Hospitals Pvt Ltd (ASHPL/ Apollo Cradle) and Apollo Fertility Centres Private Limited (AFCPL/ Apollo Fertility), wholly owned subsidiaries of Apollo Health and Lifestyle Limited (AHLL).</p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>ASHPL</th> <th>AFCPL</th> </tr> </thead> <tbody> <tr> <td>Turnover (revenue from operations)</td> <td>351.53</td> <td>100.05</td> </tr> <tr> <td>Networth</td> <td>(153.84)</td> <td>(38.33)</td> </tr> </tbody> </table>	Particulars	ASHPL	AFCPL	Turnover (revenue from operations)	351.53	100.05	Networth	(153.84)	(38.33)
Particulars	ASHPL	AFCPL									
Turnover (revenue from operations)	351.53	100.05									
Networth	(153.84)	(38.33)									
2	Whether the transaction would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity	No. Kids Clinic India Limited ('Cloudnine') is not a related party of the Company. The transaction does not fall within the ambit of related party transactions. Promoter/promoter group/group companies do not have any interest except to the extent of the proposed investment, if any.									
3	Industry to which the entity being acquired/sold belongs	Healthcare -Maternity and Birthing									
4	Objects and effects of transaction	<p>The transaction is proposed as part of Overall business strategy.</p> <p>Upon completion, Apollo Specialty Hospitals Pvt Ltd (ASHPL/ Apollo Cradle) and Apollo Fertility Centres Private Limited (AFCPL/ Apollo Fertility) shall cease to be subsidiaries/step-down subsidiaries of the Company.</p> <p>The Company through its Subsidiary Apollo Health and Lifestyle Limited will hold 9.9% shares in Kids Clinic India Ltd.</p>									
5	Brief details of consideration	INR 1,550 Crores through combination of Cash and 9.9% Equity Stake in Kids Clinic India Ltd.									
6	Whether consideration has been determined on arm's length basis	Yes									
7	Percentage of shareholding / control acquired and/or number of shares acquired	<p>ASHPL: 2,77,981 equity shares representing 100% of the share capital.</p> <p>AFCPL: 5,00,000 equity shares representing 100% of the share capital.</p>									



8	Brief background about the entity acquired	Kids Clinic India Limited which operates under the brand name " Cloudnine" operates a chain of 46 maternity, child and fertility centres in Bengaluru, Delhi NCR, Hyderabad, Mumbai, Pune, Punjab and Chennai.
9	Nature of consideration	Cash and Equity
10	Cost of acquisition or price at which shares are acquired	AHLL would be provided a 9.90% equity stake in Kids Clinic Limited, which is valued at Rs 785 crores as part of the overall transaction related consideration
11	Any governmental or regulatory approvals required	Yes, Competition Commission of India (CCI)
12	Indicative time period for completion	October 31, 2026



**Annexure-5**

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details		
		Particulars	Apollo Hospitals North Limited (Wholly Owned Subsidiary / Transferor Company)	Apollo Hospitals Enterprise Limited (Holding Company / Transferee Company)
1	Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;			
		Paid up Capital (as of March 31, 2026)	Rs. 2750 million consisting of 27,50,00,000 equity shares of INR 10 each	Rs.718.92 million consisting of 143,784,657 equity shares of INR 5 each
		Turnover as of March 31, 2026 (INR million)	Nil Yet to commence operations	Rs. 93,262 million
2	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	Apollo Hospitals North Ltd is a Wholly Owned Subsidiary of Apollo Hospitals Enterprise Limited (Holding Company).		
3	Area of business of the entity(ies);	Healthcare Business		
4	Rationale for amalgamation/ merger;	Consolidation of its Operations and thereby optimization of costs.		
5	In case of cash consideration – amount or otherwise share exchange ratio;	Not applicable		
6	Brief details of change in shareholding pattern (if any) of listed entity.	Not applicable		



# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



20<sup>th</sup> May 2026

The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejheebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code - 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.

**Scrip Code-**  
**APOLLOHOSP**  
**ISIN INE437A01024**

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that Deloitte Haskins & Sells (Firm Registration No. 117366 W/W 100018), Chartered Accountants, Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the Audited Financial Results (both standalone and consolidated) of the Company for the year ended 31<sup>st</sup> March 2026.

Kindly take on record the same.

Thanking You

Yours faithfully  
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN  
Sr. VICE PRESIDENT - FINANCE  
AND COMPANY SECRETARY



IS/ISO 9001 : 2000

**Regd. Office :**

19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**

"Ali Towers" III Floor,  
#55, Greaves Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681

Telefax : 044 - 2829 0956

Email : investor.relations@apollohospitals.com

Website : www.apollohospitals.com